After the publication of the original article [1], we were notified the upper panel of the Fig. 1, where the patients' codes are listed, was cropped by mistake so the patients 1-8 are repeated.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068888 | PMC |
| http://dx.doi.org/10.1186/s13058-020-01265-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
Breast Cancer Res Treat
October 2024
Winship Cancer Institute, Emory University, 1365 Clifton Rd NE, Building B, Suite 4000, Atlanta, GA, 30322, USA.
Association of ESR1 Germline Variants with TP53 Somatic Variants in Breast Tumors in a Genome-wide Study.
Cancer Res Commun
June 2024
Department of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, Ohio.
Unlabelled: In breast tumors, somatic mutation frequencies in TP53 and PIK3CA vary by tumor subtype and ancestry. Emerging data suggest tumor mutation status is associated with germline variants and genetic ancestry. We aimed to identify germline variants that are associated with somatic TP53 or PIK3CA mutation status in breast tumors.
View Article and Find Full Text PDFMutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial.
JCO Precis Oncol
February 2024
Translational Research Unit, Department of Medical Oncology, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy.
Purpose: To identify prognostic circulating biomarkers to cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), we performed a mutational analysis on circulating tumor DNA (ctDNA) samples from patients included in the TREnd trial, which randomly assigned patients to receive the CDK4/6i palbociclib alone or with the endocrine treatment (ET) to which they had progressed.
Methods: Forty-six patients were enrolled in this substudy. Plasma was collected before treatment (T0), after the first cycle of therapy (T1), and at the time of progression (T2).
Author Correction: Circulating ESR1, long non-coding RNA HOTAIR and microRNA-130a gene expression as biomarkers for breast cancer stage and metastasis.
Sci Rep
February 2024
Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Mechanisms predictive of Tibetan Medicine Sophora moorcroftiana alkaloids for treatment of lung cancer based on the network pharmacology and molecular docking.
BMC Complement Med Ther
January 2024
College of Veterinary Medicine of Gansu Agricultural University, Lanzhou, 730070, Gansu, China.
Article Synopsis
- Sophora moorcroftiana (SM) contains active substances called Sophora moorcroftiana alkaloids (SMA), known for their antibacterial, antitumor, and antiparasitic effects, yet their role in lung cancer (LC) inhibition remains under-researched.
- This study involves extracting active components of SMA, screening targets related to LC using various databases, and creating a network to visualize the interactions between SMA and LC targets.
- Key findings reveal six significant alkaloids, with 33 common targets linked to both SMA and LC, indicating potential therapeutic pathways and biological processes influenced by SMA that warrant further exploration.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!